In recent years, the FDA has approved several BTK inhibitors, including ibrutinib, acalabrutinib, and zanubrutinib, for treating patients with CLL (chronic lymphocytic leukemia) and lymphoma [156, 157]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.